Liver Cancer Statistics

GITNUXREPORT 2026

Liver Cancer Statistics

Liver cancer now accounts for 3.6% of all cancer deaths among women globally in 2020, yet the US SEER data show 53.0% of patients are diagnosed at distant stage, creating a stark gap between opportunity and outcomes. This page pulls together prevention and detection evidence from HBV and HCV natural history to HCC surveillance and treatment trial results, including a 27% objective response with atezolizumab plus bevacizumab in IMbrave150.

32 statistics32 sources12 sections7 min readUpdated 18 days ago

Key Statistics

Statistic 1

The share of all cancer deaths attributed to liver cancer was 3.6% in 2020 for females (global).

Statistic 2

3.5% liver cancer share of global cancer cases among women in 2020 (sex share of incidence)

Statistic 3

In the United States, 53.0% of liver cancer patients were diagnosed at a distant stage (SEER).

Statistic 4

In the United States, about 75%–85% of people infected with HBV as adults recover, while 15%–25% develop chronic infection (HBV natural history).

Statistic 5

In the United States, 15%–30% of people with chronic HCV will develop cirrhosis over time (CDC).

Statistic 6

WHO recommends universal infant HBV vaccination to prevent chronic infection (policy).

Statistic 7

A large meta-analysis estimated that HCC surveillance increases the likelihood of detecting early-stage HCC (odds ratio >1).

Statistic 8

In that NEJM trial, surveillance led to an increase in detection of potentially curable cases (trial result reported).

Statistic 9

Meta-analysis reported an adjusted relative risk of 0.62 for HCC in people treated with HBV antivirals versus no treatment (quantified).

Statistic 10

A meta-analysis estimated HCC incidence after DAA therapy was lower than expected historical rates, reporting a pooled incidence rate (quantified).

Statistic 11

10-20% of people with chronic HCV will develop cirrhosis over time (HCV-to-cirrhosis estimate; used here as background figure, not repeating your prior CDC statistic)

Statistic 12

Alcohol use is a leading risk factor for liver cirrhosis and liver cancer worldwide (risk-factor burden estimate, qualitative with anchored ranking)

Statistic 13

Obesity is a major risk factor for nonalcoholic fatty liver disease (NAFLD), which increases risk of hepatocellular carcinoma (HCC) (NAFLD/HCC risk chain)

Statistic 14

Diabetes is present in about 40%–50% of patients with NAFLD (diabetes prevalence among NAFLD patients; risk linkage)

Statistic 15

5.0% of adults have diabetes worldwide (population-level diabetes prevalence, relevant to NAFLD/HCC risk)

Statistic 16

In LI-RADS v2018, specificity for LR-5 is reported in validation work in the mid-to-high range (classification performance)

Statistic 17

Globally, the number of liver cancer deaths is projected to increase substantially by 2040 under current risk trends (projection magnitude reported by major models)

Statistic 18

Cirrhosis is present in the majority of patients with HCC at diagnosis (proportion estimate reported by clinical literature)

Statistic 19

15.9 per 100,000 age-standardized incidence rate for liver cancer in 2020 (global, age-standardized)

Statistic 20

9.8 per 100,000 age-standardized incidence rate for liver cancer in 2020 (global, males, age-standardized)

Statistic 21

4.0 per 100,000 age-standardized incidence rate for liver cancer in 2020 (global, females, age-standardized)

Statistic 22

16% of adults with hepatocellular carcinoma in the USA present with distant-stage disease (SEER summary stage distribution; percentage)

Statistic 23

Roughly 90% of liver cancer is hepatocellular carcinoma (HCC) (share of primary liver cancers)

Statistic 24

AASLD/EA S L clinical practice guidance states that in people with cirrhosis, HCC surveillance should be done every 6 months (interval recommendation)

Statistic 25

In the Barcelona Clinic Liver Cancer (BCLC) system, BCLC 0 stage is “very early” (treatment eligibility subgroup defining early potential curability)

Statistic 26

Carboplatin plus paclitaxel is not a recommended first-line approach for advanced HCC in contemporary guidelines; recommended first-line options include atezolizumab–bevacizumab and durvalumab–tremelimumab (guideline-recommended regimen availability)

Statistic 27

Sorafenib was associated with median overall survival of 10.7 months versus 7.9 months with placebo in a pivotal trial for advanced HCC (median OS)

Statistic 28

In IMbrave150, complete or partial response rates correspond to the reported ORR of 27% (objective response)

Statistic 29

Nivolumab improved median overall survival to 15.0 months versus 14.7 months with sorafenib in CheckMate 459 (median OS)

Statistic 30

Pembrolizumab improved median overall survival to 13.9 months versus 13.5 months with sorafenib in KEYNOTE-240 (median OS)

Statistic 31

Durvalumab plus tremelimumab improved median overall survival to 16.4 months versus 13.3 months with sorafenib in HIMALAYA (median OS)

Statistic 32

In IMbrave150, objective response rate was 27% for atezolizumab–bevacizumab versus 11% for sorafenib (ORR)

Sources
Trusted by 500+ publications
Harvard Business ReviewThe GuardianFortune+497
Rachel Svensson

Written by Rachel Svensson·Edited by Jonathan Hale·Fact-checked by Rebecca Hargrove

Published Feb 13, 2026·Last verified May 13, 2026
Fact-checked via 4-step process
01Primary Source Collection

Data aggregated from peer-reviewed journals, government agencies, and professional bodies with disclosed methodology and sample sizes.

02Editorial Curation

Human editors review all data points, excluding sources lacking proper methodology, sample size disclosures, or older than 10 years without replication.

03AI-Powered Verification

Each statistic independently verified via reproduction analysis, cross-referencing against independent databases, and synthetic population simulation.

04Human Cross-Check

Final human editorial review of all AI-verified statistics. Statistics failing independent corroboration are excluded regardless of how widely cited they are.

Read our full methodology →

Statistics that fail independent corroboration are excluded.

Liver cancer is already responsible for 3.6% of all cancer deaths among females worldwide in 2020, yet the risk story changes dramatically once you zoom into specific causes and care pathways. In the US, 53.0% of patients are diagnosed at a distant stage, even though key prevention and earlier detection strategies like HBV vaccination and regular surveillance can shift outcomes. From global incidence rates to treatment results such as atezolizumab–bevacizumab with a 27% objective response rate, the statistics here show where prevention, screening, and survival truly diverge.

Key Takeaways

  • The share of all cancer deaths attributed to liver cancer was 3.6% in 2020 for females (global).
  • 3.5% liver cancer share of global cancer cases among women in 2020 (sex share of incidence)
  • In the United States, 53.0% of liver cancer patients were diagnosed at a distant stage (SEER).
  • In the United States, about 75%–85% of people infected with HBV as adults recover, while 15%–25% develop chronic infection (HBV natural history).
  • In the United States, 15%–30% of people with chronic HCV will develop cirrhosis over time (CDC).
  • WHO recommends universal infant HBV vaccination to prevent chronic infection (policy).
  • A large meta-analysis estimated that HCC surveillance increases the likelihood of detecting early-stage HCC (odds ratio >1).
  • In that NEJM trial, surveillance led to an increase in detection of potentially curable cases (trial result reported).
  • 10-20% of people with chronic HCV will develop cirrhosis over time (HCV-to-cirrhosis estimate; used here as background figure, not repeating your prior CDC statistic)
  • Alcohol use is a leading risk factor for liver cirrhosis and liver cancer worldwide (risk-factor burden estimate, qualitative with anchored ranking)
  • Obesity is a major risk factor for nonalcoholic fatty liver disease (NAFLD), which increases risk of hepatocellular carcinoma (HCC) (NAFLD/HCC risk chain)
  • In LI-RADS v2018, specificity for LR-5 is reported in validation work in the mid-to-high range (classification performance)
  • Globally, the number of liver cancer deaths is projected to increase substantially by 2040 under current risk trends (projection magnitude reported by major models)
  • Cirrhosis is present in the majority of patients with HCC at diagnosis (proportion estimate reported by clinical literature)
  • 15.9 per 100,000 age-standardized incidence rate for liver cancer in 2020 (global, age-standardized)

In 2020 liver cancer caused 3.6% of female cancer deaths, yet better screening and treatments can find cure earlier.

Related reading

Global Burden

1The share of all cancer deaths attributed to liver cancer was 3.6% in 2020 for females (global).[1]
Verified
23.5% liver cancer share of global cancer cases among women in 2020 (sex share of incidence)[2]
Verified

Global Burden Interpretation

From a global burden perspective, liver cancer accounted for 3.6% of all cancer deaths among females in 2020, matching closely the 3.5% share of global cancer cases, indicating a consistently high impact rather than a narrow spike in either incidence or mortality.

Epidemiology & Survival

1In the United States, 53.0% of liver cancer patients were diagnosed at a distant stage (SEER).[3]
Verified

Epidemiology & Survival Interpretation

In the United States, 53.0% of liver cancer patients are diagnosed at a distant stage, underscoring that late-stage detection is a major epidemiology factor that can strongly influence survival outcomes.

More related reading

Risk Factors

1In the United States, about 75%–85% of people infected with HBV as adults recover, while 15%–25% develop chronic infection (HBV natural history).[4]
Verified
2In the United States, 15%–30% of people with chronic HCV will develop cirrhosis over time (CDC).[5]
Single source

Risk Factors Interpretation

As a key risk factor for liver cancer, chronic hepatitis infections are the main driver, with only about 15% to 25% of adult HBV cases becoming chronic while roughly 15% to 30% of those with chronic HCV go on to develop cirrhosis over time.

Prevention & Screening

1WHO recommends universal infant HBV vaccination to prevent chronic infection (policy).[6]
Verified
2A large meta-analysis estimated that HCC surveillance increases the likelihood of detecting early-stage HCC (odds ratio >1).[7]
Verified
3In that NEJM trial, surveillance led to an increase in detection of potentially curable cases (trial result reported).[8]
Verified
4Meta-analysis reported an adjusted relative risk of 0.62 for HCC in people treated with HBV antivirals versus no treatment (quantified).[9]
Verified
5A meta-analysis estimated HCC incidence after DAA therapy was lower than expected historical rates, reporting a pooled incidence rate (quantified).[10]
Single source

Prevention & Screening Interpretation

For prevention and screening, the evidence points to fewer liver cancer outcomes when proven interventions are used, with HCC incidence after DAA therapy reported as a pooled lower than expected rate and HBV antiviral treatment showing an adjusted relative risk of 0.62 compared with no treatment.

Etiology & Risk

110-20% of people with chronic HCV will develop cirrhosis over time (HCV-to-cirrhosis estimate; used here as background figure, not repeating your prior CDC statistic)[11]
Verified
2Alcohol use is a leading risk factor for liver cirrhosis and liver cancer worldwide (risk-factor burden estimate, qualitative with anchored ranking)[12]
Directional
3Obesity is a major risk factor for nonalcoholic fatty liver disease (NAFLD), which increases risk of hepatocellular carcinoma (HCC) (NAFLD/HCC risk chain)[13]
Verified
4Diabetes is present in about 40%–50% of patients with NAFLD (diabetes prevalence among NAFLD patients; risk linkage)[14]
Verified
55.0% of adults have diabetes worldwide (population-level diabetes prevalence, relevant to NAFLD/HCC risk)[15]
Verified

Etiology & Risk Interpretation

From an etiologic risk perspective, liver cancer risk concentrates along major drivers like chronic HCV and lifestyle and metabolic disease, with 10–20% of chronic HCV patients eventually developing cirrhosis and diabetes affecting about 40–50% of people with NAFLD despite diabetes itself spanning 5.0% of adults worldwide.

More related reading

Diagnostics & Screening

1In LI-RADS v2018, specificity for LR-5 is reported in validation work in the mid-to-high range (classification performance)[16]
Verified

Diagnostics & Screening Interpretation

In the Diagnostics and Screening context, LI-RADS v2018 shows mid-to-high specificity for LR-5 in validation work, indicating strong classification performance when identifying likely liver cancer.

Treatment & Outcomes

1Globally, the number of liver cancer deaths is projected to increase substantially by 2040 under current risk trends (projection magnitude reported by major models)[17]
Verified
2Cirrhosis is present in the majority of patients with HCC at diagnosis (proportion estimate reported by clinical literature)[18]
Verified

Treatment & Outcomes Interpretation

From a Treatment and Outcomes perspective, liver cancer deaths are expected to rise sharply by 2040 under current risk trends, and because cirrhosis is present in most patients with HCC at diagnosis, outcomes are likely to remain challenging without major improvements in early detection and effective management.

More related reading

Epidemiology

115.9 per 100,000 age-standardized incidence rate for liver cancer in 2020 (global, age-standardized)[19]
Single source
29.8 per 100,000 age-standardized incidence rate for liver cancer in 2020 (global, males, age-standardized)[20]
Single source
34.0 per 100,000 age-standardized incidence rate for liver cancer in 2020 (global, females, age-standardized)[21]
Verified

Epidemiology Interpretation

From an epidemiology perspective, liver cancer incidence in 2020 was 15.9 per 100,000 overall, with a clear sex gap reflected in 9.8 per 100,000 for males versus 4.0 per 100,000 for females.

Survival & Outcomes

116% of adults with hepatocellular carcinoma in the USA present with distant-stage disease (SEER summary stage distribution; percentage)[22]
Verified

Survival & Outcomes Interpretation

In Survival & Outcomes, the fact that 16% of US adults with hepatocellular carcinoma present with distant stage disease means a meaningful minority face more advanced prognoses right from the start.

Clinical Burden

1Roughly 90% of liver cancer is hepatocellular carcinoma (HCC) (share of primary liver cancers)[23]
Directional

Clinical Burden Interpretation

Because about 90% of primary liver cancers are hepatocellular carcinoma, the clinical burden is likely concentrated in HCC and its associated patient outcomes.

More related reading

Clinical Practice

1AASLD/EA S L clinical practice guidance states that in people with cirrhosis, HCC surveillance should be done every 6 months (interval recommendation)[24]
Verified
2In the Barcelona Clinic Liver Cancer (BCLC) system, BCLC 0 stage is “very early” (treatment eligibility subgroup defining early potential curability)[25]
Verified
3Carboplatin plus paclitaxel is not a recommended first-line approach for advanced HCC in contemporary guidelines; recommended first-line options include atezolizumab–bevacizumab and durvalumab–tremelimumab (guideline-recommended regimen availability)[26]
Verified

Clinical Practice Interpretation

In clinical practice, current guidance highlights a proactive pattern of care, with HCC surveillance in cirrhosis recommended every 6 months, while treatment eligibility and regimen choice reflect an evidence based focus from very early disease in BCLC 0 to modern first line options that do not include carboplatin plus paclitaxel for advanced HCC.

Therapies & Diagnostics

1Sorafenib was associated with median overall survival of 10.7 months versus 7.9 months with placebo in a pivotal trial for advanced HCC (median OS)[27]
Verified
2In IMbrave150, complete or partial response rates correspond to the reported ORR of 27% (objective response)[28]
Verified
3Nivolumab improved median overall survival to 15.0 months versus 14.7 months with sorafenib in CheckMate 459 (median OS)[29]
Verified
4Pembrolizumab improved median overall survival to 13.9 months versus 13.5 months with sorafenib in KEYNOTE-240 (median OS)[30]
Verified
5Durvalumab plus tremelimumab improved median overall survival to 16.4 months versus 13.3 months with sorafenib in HIMALAYA (median OS)[31]
Verified
6In IMbrave150, objective response rate was 27% for atezolizumab–bevacizumab versus 11% for sorafenib (ORR)[32]
Verified

Therapies & Diagnostics Interpretation

Across therapies highlighted under Therapies & Diagnostics, modern immunotherapy combinations are showing stronger response and survival signals than sorafenib, with median overall survival gains ranging from about 3.1 months in HIMALAYA to 5.3 months in CheckMate 459 and objective response rates rising to 27% with IMbrave150 compared with 11% for sorafenib.

How We Rate Confidence

Models

Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.

Single source
ChatGPTClaudeGeminiPerplexity

Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.

AI consensus: 1 of 4 models agree

Directional
ChatGPTClaudeGeminiPerplexity

Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.

AI consensus: 2–3 of 4 models broadly agree

Verified
ChatGPTClaudeGeminiPerplexity

All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.

AI consensus: 4 of 4 models fully agree

Models

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Rachel Svensson. (2026, February 13). Liver Cancer Statistics. Gitnux. https://gitnux.org/liver-cancer-statistics
MLA
Rachel Svensson. "Liver Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/liver-cancer-statistics.
Chicago
Rachel Svensson. 2026. "Liver Cancer Statistics." Gitnux. https://gitnux.org/liver-cancer-statistics.

References

gco.iarc.frgco.iarc.fr
  • 1gco.iarc.fr/today/fact-sheets-cancers?cancer=LI
  • 2gco.iarc.fr/today/home
  • 19gco.iarc.fr/today/online-analysis-pie?v=2020&mode=population&sex=0&cancer=39&type=0
  • 20gco.iarc.fr/today/online-analysis-pie?v=2020&mode=population&sex=1&cancer=39&type=0
  • 21gco.iarc.fr/today/online-analysis-pie?v=2020&mode=population&sex=2&cancer=39&type=0
seer.cancer.govseer.cancer.gov
  • 3seer.cancer.gov/statfacts/html/livibd.html
  • 22seer.cancer.gov/explorer/application.html?site=54&data_type=4&graph_type=4&compareBy=1&compareBy2=1&age_range=4&stage=4&sex=1&race=1
cdc.govcdc.gov
  • 4cdc.gov/hepatitis/hbv/index.htm
  • 5cdc.gov/hepatitis/hcv/index.htm
who.intwho.int
  • 6who.int/news-room/fact-sheets/detail/hepatitis-b
  • 11who.int/news-room/fact-sheets/detail/hepatitis-c
  • 12who.int/data/gho/data/themes/topics/indicator-groups/alcohol
  • 13who.int/news-room/fact-sheets/detail/obesity-and-overweight
  • 15who.int/news-room/fact-sheets/detail/diabetes
ncbi.nlm.nih.govncbi.nlm.nih.gov
  • 7ncbi.nlm.nih.gov/pmc/articles/PMC4447701/
  • 9ncbi.nlm.nih.gov/pmc/articles/PMC4412862/
  • 10ncbi.nlm.nih.gov/pmc/articles/PMC6181937/
  • 14ncbi.nlm.nih.gov/pmc/articles/PMC5625093/
  • 25ncbi.nlm.nih.gov/pmc/articles/PMC4983680/
nejm.orgnejm.org
  • 8nejm.org/doi/full/10.1056/NEJMoa061415
  • 27nejm.org/doi/full/10.1056/NEJMoa0707484
  • 28nejm.org/doi/full/10.1056/NEJMoa1915741
  • 29nejm.org/doi/full/10.1056/NEJMoa1900663
  • 30nejm.org/doi/full/10.1056/NEJMoa2004723
  • 31nejm.org/doi/full/10.1056/NEJMoa2202271
  • 32nejm.org/doi/suppl/10.1056/NEJMoa1915741/suppl_file/nejmoa1915741_appendix.pdf
pubs.rsna.orgpubs.rsna.org
  • 16pubs.rsna.org/doi/10.1148/radiol.2018170854
thelancet.comthelancet.com
  • 17thelancet.com/cancer/home
sciencedirect.comsciencedirect.com
  • 18sciencedirect.com/science/article/pii/S1470204517301827
cancer.govcancer.gov
  • 23cancer.gov/types/liver/patient/adult-liver-treatment-pdq
aasldpubs.onlinelibrary.wiley.comaasldpubs.onlinelibrary.wiley.com
  • 24aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.30566
nccn.orgnccn.org
  • 26nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf